CHA₂DS₂-VASc Score Calculator (AFib Stroke Risk) — Rounds AI
Loading...
Citation-first clinical tool

CHA₂DS₂-VASc Score Calculator (AFib Stroke Risk)

The CHA₂DS₂-VASc score estimates annual ischaemic stroke and systemic embolism risk in non-valvular atrial fibrillation. It assigns one or two points to congestive heart failure, hypertension, age, diabetes, prior stroke or thromboembolism, vascular disease, and sex category, for a total of 0–9. The ACC/AHA/HRS 2019 atrial fibrillation focused update incorporates CHA₂DS₂-VASc as the standard stratification tool for selecting patients who may benefit from oral anticoagulation. The score does not by itself dictate therapy — it is a decision-support input that clinicians integrate with bleeding risk, comorbid burden, valve status, and patient preferences.

This tool is for educational and decision-support use only. It does not replace independent clinical judgement. Always verify against the current guideline, FDA label, or specialty reference cited below before acting. Do not enter patient identifiers (name, MRN, dates of service).

Tool

≥ 75 = 2 pts; 65–74 = 1 pt
ACC/AHA/HRS 2019 Focused Update on Atrial Fibrillation (2019) — ACC / AHA / HRS — read source Primary publication: Lip GYH et al., Chest 2010 (refining stroke risk in AF)

Who this is for

  • Internal medicine and cardiology residents managing AF on rounds
  • Hospitalists and emergency physicians making acute decisions
  • Primary care attendings and APPs evaluating chronic AF

How to interpret the result

Score / bandInterpretation
0Low — anticoagulation often not recommended (men); women without other risk factors may also defer.
1Borderline — guidelines suggest considering anticoagulation (men); discuss benefits and bleeding risk.
≥ 2 (men) / ≥ 3 (women)Anticoagulation is typically recommended pending bleeding risk assessment.

Frequently asked questions

What CHA₂DS₂-VASc score warrants anticoagulation?
The ACC/AHA/HRS 2019 update suggests anticoagulation is typically reasonable at a CHA₂DS₂-VASc of ≥ 2 in men and ≥ 3 in women, after weighing bleeding risk. A score of 1 in men or 2 in women is a borderline range where shared decision-making applies. Always verify against the current guideline.
Does CHA₂DS₂-VASc apply to valvular AF?
No. CHA₂DS₂-VASc was validated in non-valvular AF. Patients with mechanical heart valves or moderate-to-severe mitral stenosis are commonly anticoagulated regardless of score, per separate guideline recommendations.
Should I use CHA₂DS₂-VASc for atrial flutter?
Most guidelines extend the CHA₂DS₂-VASc framework to atrial flutter because thromboembolic risk is presumed similar. Verify against the cited 2019 ACC/AHA/HRS update for the current language.
Does CHA₂DS₂-VASc replace HAS-BLED?
No — they are complementary. CHA₂DS₂-VASc estimates stroke risk; HAS-BLED estimates major-bleeding risk on anticoagulation. Use both together when evaluating whether to start, continue, or pause anticoagulation.
Is the CHA₂DS₂-VASc calculator a substitute for clinical judgement?
No. This tool is a decision-support aid only. It does not account for valve status, prior bleeding events, fall risk, frailty, drug interactions, or patient preferences. Final anticoagulation decisions are made by the clinician.
Ask in Rounds